Day One Biopharmaceuticals, Inc.
Clinical trials sponsored by Day One Biopharmaceuticals, Inc., explained in plain language.
Develops targeted therapies for pediatric cancer patients.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug XMT-1660 enters first human tests for Hard-to-Treat cancers Results expected Feb 2027 (estimated)
- New pill may replace chemo for kids with brain tumors Results expected Jun 2027 (estimated) 🚀 Make-or-break
-
Experimental HER2 cancer drug trial halted early
Disease control Stopped earlyThis was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.
Phase 1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets genetic weakness in tough cancers
Disease control Stopped earlyThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase 2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC